| Name | Title | Contact Details |
|---|---|---|
Sophie Mukadam |
Chief Operating Officer | Profile |
Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.
Comp-U-charge is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Imerjent is a Wilsonville, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vivakor is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.